Publication | Open Access

High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient

MedicineImmunologyT-cell ActivationPathologyImmune Checkpoint InhibitorAnti-pd1 TherapyHigh-grade GliomasCancer GeneticsRadiation OncologyOncologyGliomaNovel TherapyLong-term Response